Dengue, caused by infection of any of four dengue virus serotypes (DENV-1 to DENV-4), is a
mosquito-borne disease of major public health concern associated with significant morbidity …

Dengue is a highly endemic infectious disease of the tropical countries and is rapidly
becoming a global burden. It is caused by any of the 4 serotypes of dengue virus and is …

Background Takeda's live attenuated tetravalent dengue vaccine candidate (TAK-003) is
under evaluation in a long-term clinical trial across 8 dengue-endemic countries. Previously …

Background A substantial unmet need remains for safe and effective vaccines against
dengue virus disease, particularly for individuals who are dengue-naive and those younger …

Background Although a vaccine could be available as early as 2016, vector control remains
the primary approach used to prevent dengue, the most common and widespread arbovirus …

Microbial infection initiates complex interactions between the pathogen and the host.
Pathogens express several signature molecules, known as pathogen-associated molecular …

Dengue virus poses a major threat to global public health: two-thirds of the world's
population is now at risk from infection by this mosquito-borne virus. Dengue virus causes a …

Dengue poses a global health threat, which will persist without therapeutic intervention.
Immunity induced by exposure to one serotype does not confer long-term protection against …

Dengue is widespread throughout the tropics and local spatial variation in dengue virus
transmission is strongly influenced by rainfall, temperature, urbanization and distribution of …

Background Takeda's dengue vaccine is under evaluation in an ongoing phase 3 efficacy
study; we present a 2-year update. Methods Children (20 099, 4–16 years old) were …